BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 10189134)

  • 21. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
    Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
    Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population.
    Inoue T; Segawa T; Shiraishi T; Yoshida T; Toda Y; Yamada T; Kinukawa N; Kinoshita H; Kamoto T; Ogawa O
    Urology; 2005 Aug; 66(2):332-7. PubMed ID: 16098362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma.
    Sittel C; Eckel HE; Damm M; von Pritzbuer E; Kvasnicka HM
    Laryngoscope; 2000 Jun; 110(6):1012-7. PubMed ID: 10852523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
    Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
    Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
    May M; Siegsmund M; Hammermann F; Loy V; Gunia S
    Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
    Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
    Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
    Sasor A; Wagrowska-Danilewicz M; Danilewicz M
    Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer.
    Leibovich BC; Cheng L; Weaver AL; Myers RP; Bostwick DG
    J Urol; 2000 Jun; 163(6):1756-60. PubMed ID: 10799176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship of the histologic grade at the deep invasive front and the expression of Ki-67 antigen and p53 protein in oral squamous cell carcinoma.
    Kurokawa H; Zhang M; Matsumoto S; Yamashita Y; Tanaka T; Tomoyose T; Takano H; Funaki K; Fukuyama H; Takahashi T; Sakoda S
    J Oral Pathol Med; 2005 Nov; 34(10):602-7. PubMed ID: 16202080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
    Bianco FJ; Scardino PT; Stephenson AJ; Diblasio CJ; Fearn PA; Eastham JA
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):448-53. PubMed ID: 15890586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis.
    Erdamar S; Yang G; Harper JW; Lu X; Kattan MW; Thompson TC; Wheeler TM
    Mod Pathol; 1999 Aug; 12(8):751-5. PubMed ID: 10463475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy.
    Leibovici D; Chiong E; Pisters LL; Guo CC; Ward JF; Andino L; Prokhorova IN; Troncoso P
    J Urol; 2012 Jul; 188(1):98-102. PubMed ID: 22578724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between histological type and immunohistochemical profile of prostate cancer and gleason scale gradation.
    Iemelynova AA; Grygorenko VM; Cheremuha SV; Romanenko AM
    Exp Oncol; 2009 Dec; 31(4):246-9. PubMed ID: 20010526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
    Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
    Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
    Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
    Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
    Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 protein and gene alterations in pathological stage C prostate carcinoma.
    Salem CE; Tomasic NA; Elmajian DA; Esrig D; Nichols PW; Taylor CR; Skinner DG; Roy-Burman P; Lieskovsky G; Cote RJ
    J Urol; 1997 Aug; 158(2):510-4. PubMed ID: 9224335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoreactive p53 protein in high-grade prostatic intraepithelial neoplasia.
    Humphrey PA; Swanson PE
    Pathol Res Pract; 1995 Sep; 191(9):881-7. PubMed ID: 8606869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.